McKesson stock at EUR 1,001.75, down 0.91% premarket
Published on 11/17/2026 at 07:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMcKesson outlook supports investor focus
- McKesson raised fiscal 2027 adjusted EPS guidance to USD 45.60-46.40 after second-quarter results.
- Higher-margin oncology and technology businesses are becoming more important to the company's earnings mix.
- Investors are watching execution in specialty care, the planned Medical-Surgical separation and the proposed Option Care investment.
McKesson faces a softer premarket
McKesson stock traded at EUR 1,001.75 on Lang & Schwarz at 07:57 CET on Tuesday, November 17, 2026, 0.91 percent below the Xetra close of Monday, November 16, 2026, at EUR 1,011.00.
The pharmaceutical distributor raised its fiscal 2027 adjusted earnings guidance after second-quarter results released on November 4. According to CNBC, the new range is USD 45.60 to USD 46.40 per adjusted share, up from USD 44.20 to USD 45.00. The company serves pharmacies, hospitals and clinics through pharmaceutical distribution and healthcare services.
McKesson's earnings mix is shifting toward higher-margin oncology and technology operations. CNBC reported that these businesses generated about 37 percent of adjusted segment operating profit while accounting for approximately 15 percent of second-quarter revenue. The Medical-Surgical business remains weaker, with management expecting full-year segment profit to range from a 4 percent decline to flat.
The planned separation of Medical-Surgical Solutions, the proposed investment in Option Care Health and the extension of McKesson's distribution partnership with CVS Health remain important strategic developments. The Option Care transaction is expected to close in the first half of 2027, while the Medical-Surgical business is expected to be renamed Wellverse before a planned initial public offering in the second half of 2027.
Broader healthcare stocks can be followed through the S&P 500.
